Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Borrello

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
Blood Advances|December 16, 2017
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamideYvette L Kasamon, Richard F Ambinder, Ephraim J Fuchs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete RemissionLuca Biavati, Carol Ann Huff, Anna Ferguson, et al.
Science Translational Medicine|May 22, 2015
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myelomaKimberly A Noonan, Carol A Huff, Janice Davis, et al.
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
Leukemia & Lymphoma|August 22, 2015
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamideLindsey R Lombardi, Christopher G Kanakry, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2017
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2018
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationYvette L Kasamon, Ephraim J Fuchs, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA FactorsJennifer A Kanakry, Christopher D Gocke, Javier Bolaños-Meade, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 2, 2019
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
Blood Advances|December 16, 2017
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamideYvette L Kasamon, Richard F Ambinder, Ephraim J Fuchs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete RemissionLuca Biavati, Carol Ann Huff, Anna Ferguson, et al.
Science Translational Medicine|May 22, 2015
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myelomaKimberly A Noonan, Carol A Huff, Janice Davis, et al.
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
Leukemia & Lymphoma|August 22, 2015
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamideLindsey R Lombardi, Christopher G Kanakry, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2017
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2018
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationYvette L Kasamon, Ephraim J Fuchs, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA FactorsJennifer A Kanakry, Christopher D Gocke, Javier Bolaños-Meade, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 2, 2019
Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Pageof 9